Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1024731

	registered interest
	date	13/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mental Health Services: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the briefing published by the Children's Commissioner entitled Children’s Mental Healthcare in England published November 2018, what steps his Department is taking to reduce waiting times for children with mental health problems.
	tabling member constituency	Barnsley Central
	tabling member printed	Dan Jarvis
	uin	202100
	answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>We have made an additional £1.4 billion available for children’s mental health service transformation and are on track to ensure that an additional 70,000 children and young people access community mental health services annually by 2020/21.</p><p> </p><p>We have introduced two waiting time standards for children and young people and are on track to meet both of these standards. The first aims for 95% of children (up to 19 years old) with eating disorders to receive treatment within a week for urgent cases and four weeks for routine cases. The second aims for 50% of patients of all ages experiencing a first episode of psychosis to receive treatment within two weeks of referral.</p><p> </p><p>Our Children and Young People’s Green Paper, jointly published with the Department for Education, sets out how we plan to go further. We are piloting a four-week waiting time to improve access to services and are introducing new mental health support teams. Trailblazer sites, where we plan to test our Green Paper proposals, will be announced shortly.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 18/12/2018 14:36:32 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4243 label Biography information for Dan Jarvis

1024687

	registered interest
	date	13/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rare Diseases: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that there is no disparity in access to treatments for rare diseases between the UK and economically similar countries in Europe.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	202087
	answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>The Government is committed to the safe and effective regulation of medicines in the United Kingdom; ensuring patients and the public have fast access to new, innovative medicines, including medicines for rare diseases.</p><p> </p><p>The agreement of an implementation period will ensure that access to medicines continues, and patient safety is maintained, in both the UK and European Union markets. Beyond that, the Political Declaration sets out a plan for a free trade area for goods, underpinned by deep regulatory co-operation, as well as a joint commitment to explore close cooperation with the European Medicines Agency.</p><p> </p><p>The Government also continues to prepare for the unlikely outcome that we leave the EU without any deal in March 2019. The Department has been engaging with all pharmaceutical companies that supply the United Kingdom with pharmacy or prescription-only medicines from, or via, the EU/European Economic Area, on their contingency plans in the event of a no deal EU exit.</p><p> </p><p>Whatever the exit scenario, we will continue to ensure that UK patients are able to access the best and most innovative medicines including medicines for rare diseases and that their safety is protected.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 18/12/2018 17:36:24 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4249 label Biography information for Anne Marie Morris

1024698

	registered interest
	date	13/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Orphan Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he is taking steps to introduce a revised definition for ultra-orphan medicine.
	tabling member constituency	Linlithgow and East Falkirk
	tabling member printed	Martyn Day
	uin	202090
	answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>Currently, rare diseases are defined as conditions affecting no more than five in 10,000 people in the European Union. The new European Clinical Trial Regulation (Regulation (EU) No 536/2014) will introduce an ‘ultra-rare’ condition and states that clinical trials for the development of orphan medicinal products and those of medicines affecting no more than one person in 50,000 in the EU (ultra-rare diseases) should be fostered, and in such areas, a rapid yet in-depth assessment is of particular importance. The new clinical trials regulation is expected to be implemented in the EU in late 2020. The Government has confirmed that United Kingdom law will remain aligned with the parts of the new EU clinical trials Regulation that are within the UK’s control.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 20/12/2018 17:10:46 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4488 label Biography information for Martyn Day

1024700

	registered interest
	date	13/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rare Diseases: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the UK remains a world leader for the treatment of rare diseases after the UK leaves the EU.
	tabling member constituency	Linlithgow and East Falkirk
	tabling member printed	Martyn Day
	uin	202091
	answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>The Government is committed to the safe and effective regulation of medicines in the United Kingdom; ensuring patients and the public have fast access to new, innovative medicines, including medicines for rare diseases.</p><p> </p><p>The agreement of an implementation period will ensure that access to medicines continues, and patient safety is maintained, in both the UK and European Union markets. Beyond that, the Political Declaration sets out a plan for a free trade area for goods, underpinned by deep regulatory co-operation, as well as a joint commitment to explore close cooperation with the European Medicines Agency.</p><p> </p><p>The Government also continues to prepare for the unlikely outcome that we leave the EU without any deal in March 2019. The Department has been engaging with all pharmaceutical companies that supply the United Kingdom with pharmacy or prescription-only medicines from, or via, the EU/European Economic Area, on their contingency plans in the event of a no deal EU Exit.</p><p> </p><p>Whatever the exit scenario, we will work to ensure that the UK will remain a world leader for the treatment of rare diseases after the UK leaves the EU, that UK patients are able to access the best and most innovative medicines including medicines for rare diseases and that their safety is protected. The UK life sciences industry has much to offer in creating, developing, trialing and commercialising medicines that will benefit UK patients and strengthen the ability of the UK to compete internationally.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 20/12/2018 17:07:43 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4488 label Biography information for Martyn Day

1024791

	registered interest
	date	13/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Eating Disorders
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 10 December 2018 to Question 197605, whether the long-term plan for the NHS will address regional variations in access to specialist support for adults with eating disorders.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	202083
	answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>Mental health will be a core part of the National Health Service long-term plan, including building on the improvements in providing access to good mental health services. The NHS long-term plan is currently in development and will be published shortly by NHS England.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 18/12/2018 14:37:26 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1439 label Biography information for Norman Lamb